Phosphodiesterase 4 inhibitors vs placebo
Number experiencing adverse effects · patients with stable chronic obstructive pulmonary disease
Phosphodiesterase‐4 inhibitors may leads to higher number of participants experiencing an adverse event compared with placebo (low certainty).
1 finding from 1 review
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyOR 1.3 [1.22, 1.38]30 studies · 21310 participantsLow